The American Diabetes Association (ADA) recommends assessment of 10-year atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes and discusses appropriate use of the ASCVD calculator.
The comparison of dipeptidyl peptidase-4 inhibitors with other drug classes did find higher rates of major adverse cardiovascular events with basal insulin, sulfonylureas, and meglitinides than with the newer drugs.
An editorial noted that drug-eluting stents may work for noncomplex lesions in patients with diabetes, but complex disease states incurred high rates of myocardial infarction and revascularization.
This month's quiz asks readers to evaluate a 48-year-old woman with type 2 diabetes who has recently had elevated liver chemistry test results.
In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years
The results of a recent trial of aspirin for cardiovascular disease (CVD) prevention in diabetes challenge current guidelines and the opinion of many clinicians of the net benefit of the drug, according to an ACP Journal Club commentary.
Although canagliflozin has been linked to decreased bone mineral density, patients with type 2 diabetes who initiated the drug had similar risk of a first fracture as those who started a glucagon-like peptide-1 receptor agonist.